S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
Critical asset just had biggest fall on record (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
NASDAQ:MXCT

MaxCyte (MXCT) Stock Price, News & Analysis

$4.65
+0.11 (+2.42%)
(As of 02/27/2024 ET)
Today's Range
$4.50
$4.68
50-Day Range
$4.42
$5.38
52-Week Range
$2.45
$5.55
Volume
327,486 shs
Average Volume
684,928 shs
Market Capitalization
$483.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

MaxCyte MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.3% Upside
$9.50 Price Target
Short Interest
Healthy
3.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$176,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.40) to ($0.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

Medical Sector

350th out of 944 stocks

Commercial Physical Research Industry

6th out of 13 stocks


MXCT stock logo

About MaxCyte Stock (NASDAQ:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

MXCT Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MaxCyte Signs SPL Agreement With Imugene
COMM, NKTX and AVIR are among after hour movers
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
MaxCyte gets new CEO and President
MaxCyte Names Maher Masoud CEO
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
MaxCyte Inc MXCT
Why Is MaxCyte (MXCT) Stock Down 21% Today?
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/28/2024
Next Earnings (Confirmed)
3/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:MXCT
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$12.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+104.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-23,570,000.00
Pretax Margin
-98.44%

Debt

Sales & Book Value

Annual Sales
$44.26 million
Book Value
$2.47 per share

Miscellaneous

Free Float
97,769,000
Market Cap
$483.65 million
Optionable
Optionable
Beta
1.44
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Maher Masoud (Age 48)
    President, CEO, Secretary & Director
    Comp: $612.07k
  • Mr. Douglas Arthur Doerfler (Age 68)
    Founder & Advisor
    Comp: $1.2M
  • Mr. Douglas J. Swirsky CFA (Age 55)
    CPA, Chief Financial Officer
  • Mr. Jay Gelfman
    Senior Vice President of Operations
  • Mr. Ronald Evan Holtz CPA (Age 66)
    Ph.D., Executive Vice President of Administration
    Comp: $649.38k
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. Thomas Michael Ross (Age 63)
    Executive Vice President of Global Sales
  • Mr. Jack Horgan
    Vice President of Corporate Development
  • Dr. J. Stark Thompson Ph.D. (Age 82)
    Consultant
    Comp: $84.71k
  • Dr. James Brady Ph.D.
    Senior VP of Technical Applications & Customer Support














MXCT Stock Analysis - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings
or view top-rated stocks.

What is MaxCyte's stock price target for 2024?

3 brokers have issued 12-month target prices for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $12.00. On average, they expect the company's share price to reach $9.50 in the next year. This suggests a possible upside of 104.3% from the stock's current price.
View analysts price targets for MXCT
or view top-rated stocks among Wall Street analysts.

How have MXCT shares performed in 2024?

MaxCyte's stock was trading at $4.70 at the beginning of the year. Since then, MXCT stock has decreased by 1.1% and is now trading at $4.65.
View the best growth stocks for 2024 here
.

When is MaxCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our MXCT earnings forecast
.

How can I listen to MaxCyte's earnings call?

MaxCyte will be holding an earnings conference call on Tuesday, March 12th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

What guidance has MaxCyte issued on next quarter's earnings?

MaxCyte issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $15.5 million-$15.7 million, compared to the consensus revenue estimate of $10.7 million.

When did MaxCyte IPO?

(MXCT) raised $150 million in an IPO on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

MaxCyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include Cadian Capital Management LP (5.43%), Vanguard Group Inc. (5.08%), Massachusetts Financial Services Co. MA (2.44%), Mudita Advisors LLP (1.81%), River Global Investors LLP (1.46%) and Granahan Investment Management LLC (1.37%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross.
View institutional ownership trends
.

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MXCT) was last updated on 2/28/2024 by MarketBeat.com Staff